Fractyl Health (NASDAQ:GUTS) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Key Points

• Fractyl Health reported quarterly EPS of ($0.16), missing analysts’ consensus estimate of ($0.14) by $0.02.
• Shares fell $0.02 to $0.68, with the company’s market capitalization near $107 million and its stock trading between a 52-week low of $0.38 and high of $2.44.
• Analyst sentiment remains a “Moderate Buy”, with a consensus price target of $5.12, while insiders purchased 171,493 shares worth approximately $127,150 over the past 90 days.

Fractyl Health (NASDAQ:GUTS - Get Free Report) issued its earnings results on Monday. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02), FiscalAI reports.

Fractyl Health Stock Performance

NASDAQ:GUTS traded down $0.02 on Monday, hitting $0.68. The stock had a trading volume of 1,482,402 shares, compared to its average volume of 3,386,256. The business's 50-day simple moving average is $0.77 and its two-hundred day simple moving average is $0.71. The stock has a market cap of $107.09 million, a price-to-earnings ratio of -0.52 and a beta of 2.32. Fractyl Health has a 52-week low of $0.38 and a 52-week high of $2.44. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 1.41.

Insider Activity

In other Fractyl Health news, Director Ian Sheffield bought 35,000 shares of the business's stock in a transaction that occurred on Wednesday, June 10th. The stock was bought at an average cost of $0.73 per share, for a total transaction of $25,550.00. Following the completion of the transaction, the director owned 35,000 shares of the company's stock, valued at $25,550. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William Bradley bought 68,493 shares of the business's stock in a transaction that occurred on Wednesday, June 10th. The shares were acquired at an average price of $0.73 per share, with a total value of $49,999.89. Following the completion of the transaction, the director directly owned 84,622 shares of the company's stock, valued at $61,774.06. This trade represents a 424.66% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 171,493 shares of company stock valued at $127,150 in the last ninety days. Insiders own 8.52% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GUTS. Nantahala Capital Management LLC bought a new stake in shares of Fractyl Health during the 3rd quarter valued at $19,298,000. Marshall Wace LLP raised its holdings in Fractyl Health by 234.9% in the 4th quarter. Marshall Wace LLP now owns 5,926,745 shares of the company's stock worth $13,039,000 after purchasing an additional 4,156,969 shares during the period. Alyeska Investment Group L.P. purchased a new position in Fractyl Health during the third quarter valued at $8,981,000. Woodline Partners LP lifted its position in Fractyl Health by 821.1% during the third quarter. Woodline Partners LP now owns 5,506,534 shares of the company's stock valued at $8,755,000 after purchasing an additional 4,908,693 shares in the last quarter. Finally, General Catalyst Group Management LLC bought a new stake in Fractyl Health during the second quarter valued at about $7,912,000.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GUTS. Wall Street Zen raised shares of Fractyl Health from a "strong sell" rating to a "hold" rating in a report on Saturday, May 16th. HC Wainwright restated a "buy" rating and set a $8.00 price objective on shares of Fractyl Health in a research report on Thursday, June 4th. Weiss Ratings cut shares of Fractyl Health from a "sell (d-)" rating to a "sell (e+)" rating in a report on Thursday. Finally, Craig Hallum started coverage on shares of Fractyl Health in a research report on Wednesday, July 1st. They issued a "buy" rating and a $4.00 target price for the company. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $5.12.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company's lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source